Author | Luetkemeyer, Anne F. | |
Author | Rosenkranz, Susan L. | |
Author | Lu, Darlene | |
Author | Grinsztejn, Beatriz | |
Author | Sanchez, Jorge | |
Author | Ssemmanda, Michael | |
Author | Sanne, Ian | |
Author | McIlleron, Helen | |
Author | Havlir, Diane V. | |
Author | Haas, David W. | |
Access date | 2018-10-11T18:27:44Z | |
Available date | 2018-10-11T18:27:44Z | |
Document date | 2015 | |
Citation | LUETKEMEYER, Anne F. et al. Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-Based Antituberculosis Therapy in the STRIDE Study. Clinical Infectious Diseases, v. 60, n. 12, p. 1860-1863, 2015. | pt_BR |
ISSN | 1058-4838 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/29549 | |
Language | eng | pt_BR |
Rights | restricted access | pt_BR |
Title | Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study | pt_BR |
Type | Article | pt_BR |
DOI | 10.1093/cid/civ155 | |
Abstract | In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations. | pt_BR |
Affilliation | University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, USA. | pt_BR |
Affilliation | Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA. | pt_BR |
Affilliation | Harvard School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | IMPACTA. Lima, Peru. | pt_BR |
Affilliation | Joint Clinical Research Center. Kampala, Uganda. | pt_BR |
Affilliation | University of the Witwatersrand. Faculty of Health Sciences. Johannesburg, South Africa. | pt_BR |
Affilliation | University of Cape Town. Department of Medicine. Division of Clinical Pharmacology Cape Town, South Africa. | pt_BR |
Affilliation | University of California. San Francisco General Hospital. HIV/AIDS Division. San Francisco, USA. | pt_BR |
Affilliation | Vanderbilt University School of Medicine. Department of Medicine. Nashville, Tennessee, USA. | pt_BR |
Subject | HIV/AIDS | pt_BR |
Subject | Efavirenz | pt_BR |
Subject | Pharmacogenetic | pt_BR |
Subject | Rifampin | pt_BR |
Subject | Tuberculosis | pt_BR |
Subject | Adult AIDS Clinical Trials Group A5221 Study Team | pt_BR |
Subject | A5243 Study Team | pt_BR |
Embargo date | 2028-08-30 | |